Results 101 to 110 of about 3,627,754 (377)

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

Mizoribine Inhibits the Proliferation of Renal Stem/Progenitor Cells by G1/S Arrest during Renal Regeneration [PDF]

, 2014
Immunosuppressive agents are generally administered to treat kidney diseases. However, it is unclear whether renal stem/progenitor cells are directly affected by the immunosuppressive agents.
Horimoto, Naoya, Kitamura, Shinji, Makino, Hirofumi, Tsuji, Kenji   +3 more
core   +1 more source

Prevalence, determinants and outcomes of low disease activity and remission attainment in SLE patients with clinically active disease

Arthritis Care &Research, Accepted Article.
Objectives This study aimed to identify the frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS‐remission) attainment in systemic lupus erythematosus (SLE) patients with clinically active disease, and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Kristine (Pek Ling) Ng, Annie Law, BMDB Basnayake, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Shirley Chan, CS Lau, Vera Golder, Alberta Hoi, Shereen Oon, Eric Morand, Mandana Nikpour, for the Asia Pacific Lupus Collaboration   +39 more
wiley   +1 more source

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

Arthritis Research & Therapy, 2020
Background European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc’s optimal management.
S. Panopoulos, Κ. Chatzidionysiou, M. G. Tektonidou, V. K. Bournia, A. A. Drosos, Stamatis-Nick C. Liossis, T. Dimitroulas, L. Sakkas, D. Boumpas, P. V. Voulgari, D. Daoussis, K. Thomas, G. Georgiopoulos, G. Vosvotekas, Α. Garyfallos, P. Sidiropoulos, G. Bertsias, D. Vassilopoulos, P. P. Sfikakis   +18 more
doaj   +1 more source

Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis

Arthritis Care &Research, EarlyView.
Objective Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early ...
Zoe Rutter‐Locher, Sam Norton, Joseph L. Taylor, Bina Menon, Tom Esterine, Ruth Williams, Leonie S. Taams, Kirsty Bannister, Bruce W. Kirkham   +8 more
wiley   +1 more source

Assessment of skin in patients with systemic sclerosis using high‐frequency ultrasound and shear wave elastography: A comparative study with histology, molecular and clinical parameters

Arthritis Care &Research, Accepted Article.
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histological markers of skin fibrosis has not been reported. We evaluated the US‐based skin assessments for their face validity (differentiation between involved SSc and ...
Ruhani Desai, Filemon Tan, Minghua Wu, Jeffery L. Browning, Samuel Theodore, Meng Zhang, Brian Skaug, Harshdeep Singh Chawla, Manmohan Singh, Salavat Aglyamov, Kirill V. Larin, Maureen Mayes, Shervin Assassi   +12 more
wiley   +1 more source

Beyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis

Arthritis Care &Research, EarlyView.
Persistent pain remains a major challenge in inflammatory arthritis, even when joint inflammation is well controlled. Pain and associated symptoms such as fatigue cannot be explained by peripheral inflammation alone but reflect altered central pain processing. These changes may arise through “top‐down” mechanisms, reflecting pre‐existing dysfunction in
Eoin M. Kelleher, Rosario Meouchi, Anushka Irani   +2 more
wiley   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Immunosuppressive drugs and major complications in pediatric renal transplantation

Iatreia, 2017
Pediatric renal transplantation is the treatment of choice in children with chronic kidney disease. Many agents are available for immunosuppressive therapy, which are used in two different regimes: first for the induction phase, and then for maintenance.
Guerrero-Tinoco, Gustavo Adolfo, Villafañe-Bermúdez, Douglas Ramón, Vélez-Echeverri, Catalina   +2 more
doaj   +1 more source

Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom [PDF]

, 2011
PURPOSE: Ocular mucous membrane pemphigoid (OcMMP) is a sight-threatening autoimmune disease in which referral to specialists units for further management is a common practise.
AH Ross, BA Rice, BJ Mondino, BJ Mondino, C Radford, CS Foster, CS Foster, CS Yee, D Gladman, E Daniel, E Miserocchi, EH Sacks, G P Williams, GP Williams, H John, J K G Dart, J Risser, J Sheppard, J Tauber, J Tauber, J Tauber, JA Taverna, JE Thorne, JE Thorne, LS Chan, LS Chan, M Ahmed, MJ Canizares, MJ Elder, MJ Elder, MJ Elder, MJ Elder, MP Heffernan, P Nightingale, RJ Barry, RS Rogers III, S Rauz, S Rauz, S Segura, SJ Bowman, VP Saw, VP Saw, W Bernauer, W Bernauer, W Bernauer, W Bernauer   +45 more
core   +2 more sources